Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-08-04
2011-12-13
Landsman, Robert (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C514S019100, C530S350000, C530S387100
Reexamination Certificate
active
08076086
ABSTRACT:
The invention provides isolated nucleic acids encoding a variety of proteins and nucleic acids having diagnostic, preventive, therapeutic, and other uses. These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
REFERENCES:
patent: 5635370 (1997-06-01), Hockfield et al.
patent: 6960651 (2005-11-01), Kirst et al.
patent: WO 95/26201 (1995-10-01), None
patent: WO 98/31800 (1998-07-01), None
patent: WO 98/39446 (1998-09-01), None
patent: WO 98/52590 (1998-11-01), None
patent: WO 99/06554 (1999-02-01), None
patent: WO 99/14327 (1999-03-01), None
patent: WO 99/14328 (1999-03-01), None
patent: WO 00/05367 (2000-02-01), None
patent: WO 00/75317 (2000-12-01), None
Better, et al., “Escherichia coliSecretion of an Active Chimeric Antibody Fragment,” Science, 240:1041-43 (May 20, 1988).
Houghten, et al., “The Use of Synthetic Peptide Combinatorial Libraries for the Identification of Bioactive Peptides,” BioTechniques, 13:412-20 (1992).
Inagaki, et al., “Identification of a member of mouse semaphoring family,” FEBS Lett., 370:269-72 (1995).
Itoh, et al., “Cloning and expressions of three mammalian homologues ofDrosophila slitsuggest possible roles forSlitin the formation and maintenance of the nervous system,” Molecular Brain Research, 62:175-86 (1998).
Kohler, et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, 256:495-7 (1975).
Kulman, et al., “Primary structure and tissue distribution of two novel proline-rich •-carboxyglutamic acid proteins,” Proc. Natl. Acad. Sci. USA, 94-9058-62 (Aug. 1997).
Liu, et al., “Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells,” Proc. Natl. Acad. Sci. USA, 84:3439-43 (May 1987).
Liu, et al., Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity, J. Immunol., 139:3521-6 (Nov. 15, 1987).
Miura, et al., “The Proteoglycan Lectin Domain Binds Sulfated Cell Surface Glycolipids and Promotes Cell Adhesion,” J. Biol. Chem., 274:11431-8 (Apr. 16, 1999).
Nishimura, et al., “Recombinant Human-Mouse Chimeric Monoclonal Antibody Specific for Common Acute Lymphocytic Leukemia Antigen,” Cancer Res., 47:999-1005 (Feb. 15, 1987).
Shaw, et al., “Mouse/Human Chimeric Antibodies to a Tumor-Associated Antigen: Biologic Activity of the Four Human IgG Subclasses,” J. Natl. Cancer Inst., 80:1553-9 (Dec. 7, 1988).
Sun, et al., “Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A,” Proc. Natl. Acad. Sci. USA, 84:214-18 (Jan. 1987).
Wood, et al., “The synthesis and in vivo assembly of functional antibodies in yeast,” Nature, 314:446-9 (Apr. 1985).
Zhang, et al., “Expression of a Cleaved Brain-Specific Extracellular Matrix Protein Mediates Glioma Cell Invasion in Vivo,” J. Neurosci., 18:2370-6 (Apr. 1, 1998).
Hofsteenge., et al., “Ribonuclease Inhibitor,” created Jul. 1, 1989 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on Feb. 9, 2000]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/>. Swiss Prot Accession No. P10775.
Chen, et al., “Cricetulus griseus HT protein mRNA, complete cds,” Mar. 7, 1996 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on Feb. 9, 2000]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/>. GenBank Accession No. U48852.
Giordano, et al., “Hepatocyte Growth Factor Receptor Precursor (Met Proto-Oncogene Tyrosine Kinase) (HGF-SF Receptor),” created Aug. 1, 1988 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on Feb. 9, 2000]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/>. Swiss Prot Accession No. P08581.
Maestrini, et al., “Plexin 4 Precursor (Transmembrane Protein Sex),” created Oct. 1, 1996 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on Feb. 9, 2000]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/>. Swiss Prot Accession No. P51805.
Inagaki, et al., “M-Sema F=a factor in neural network development [mice, neonatal brain, mRNA, 3503 nt],” Dec. 9, 1995 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on Feb. 9, 2000]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/>. GenBank Accession No. S79463.
Itoh, et al., “Homo sapiensmRNA for Slit-1 protein, complete cds,” Feb. 6, 1999 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on Feb. 9, 2000]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/>. GenBank Accession No. AB017167.
Kitani, et al., “Efficiency of neural differentiation of mouse P19 embryonal carcinoma cells is dependent on the seeding density,” Cell Transplant, 6(5):521-5 (1997).
Agrawal and Brauer, “Urokinase-type plasminogen activator regulates cranial neural crest cell migration in vitro, ” Dev Dyn., 207(3) (abstract only) (1996).
Goodman, et al., “Modulation of N-myc expression alters the invasiveness of neuroblastoma,” Clin Exp Metastasis, 15(2) (abstract only) (1997).
Yamada, H., et al., “Molecular Cloning of Brevican, a Novel Brain Proteoglycan of the Aggrecan/Versican family,” J. Biol. Chem. 269(13):10119-10126 (1994).
Burgess, et al., “Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor with Therapeutic Potential against Hepatocyte Growth Factor/c-Met-Dependent Human Tumors,” Cancer Res 2006, 66:1721-26 (Feb. 1, 2006).
Schulke, et al., “The Homodimer of Prostate-specific Membrane Antigen is a Functional Target for Cancer Therapy,” PNAS, vol. 100, No. 22: 12590-95 (Oct. 28, 2003).
Kohda, et al., “Solution Structure of the Link Module: A Hyaluronan-Binding Domain Involved in Extracellular Matrix Stability and Cell Migration,” Cell, vol. 86, 767-75 (Sep. 6, 1996).
Chengyao et al, Journal of Virology, Dec. 2001, pp. 12412-12420.
Natal et al, Hybridoma, vol. 19, No. 6, 2000, p. 445. Abstract only.
Berg et al, Blood, vol. 85, No. 1 Jan 1, 1995, pp. 31-37.
Dahmus et al, The Journal of Biological Chemistry, vol. 259, No. 14, Jul. 25, 1984, pp. 9001-9006.
Kraus et al, The Journal of Reproductive Immunology, vol. 65, 2005, p. 33-46.
Kharbanda, et al., “Gene expression profiling of gliomas identifies candidate genes for the development of an antibody-based therapeutic,” Proc Amer Assoc Cancer Res 2005; 46:[Abstract 4868].
Jaworski, et al., “BEHAB, a new member of the proteoglycan tandem repeat family of hyaluronanbinding proteins that is restricted to the brain,” J. Cell Biol, 125:495-509, 1994.
Seidenbecher, et al., “Brevican, a chondroitin sulfate proteoglycan of rat brain, occurs as secreted and cell surface glycosylphosphatidylinositol-anchored isoforms,” J. Biol. Chem., 270(45): 27206-27212, 1995.
Yamada, et al., “cDNA cloning and identification
Barnes Thomas S.
Fraser Christopher C.
Holtzman Douglas A.
Kirst Susan J.
Sharp John D.
Dang Ian
Landsman Robert
Millennium Pharmaceuticals Inc.
LandOfFree
Methods of modulating the activity of TANGO332 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of modulating the activity of TANGO332, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of modulating the activity of TANGO332 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4272046